95 related articles for article (PubMed ID: 19678769)
1. Comparative analysis of polymorphisms in the HIV type 1 pol gene in the proviral DNA and viral RNA in the peripheral compartment.
Rangel HR; Garzaro D; Fabro R; Fernández D; Gutiérrez CR; Martínez N; Pujol FH
AIDS Res Hum Retroviruses; 2009 Aug; 25(8):837-41. PubMed ID: 19678769
[TBL] [Abstract][Full Text] [Related]
2. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy.
Teixeira C; de Sá-Filho D; Alkmim W; Janini LM; Diaz RS; Komninakis S
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):307-11. PubMed ID: 20334566
[TBL] [Abstract][Full Text] [Related]
3. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
[TBL] [Abstract][Full Text] [Related]
4. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
5. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
7. HIV-1C proviral DNA for detection of drug resistance mutations.
Huruy K; Mulu A; Liebert UG; Maier M
PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management.
Bon I; Alessandrini F; Borderi M; Gorini R; Re MC
New Microbiol; 2007 Jul; 30(3):313-7. PubMed ID: 17802917
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
[TBL] [Abstract][Full Text] [Related]
11. Pol bootscanning analysis of HIV type 1 can exhibit unexpected recombinations.
Jeannot AC; Reigadas S; Schrive MH; Pinson P; Fleury HJ
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):713-6. PubMed ID: 19563236
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
[TBL] [Abstract][Full Text] [Related]
14. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
[TBL] [Abstract][Full Text] [Related]
15. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.
Riva E; Pistello M; Narciso P; D'Offizi G; Isola P; Galati V; Turriziani O; Tozzi V; Vincenzi L; Dianzani F; Antonelli G
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1599-604. PubMed ID: 11779347
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 proviral resistance mutations: usefulness in clinical practice.
Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.
Bon I; Turriziani O; Musumeci G; Clò A; Montagna C; Morini S; Calza L; Gibellini D; Antonelli G; Re MC
J Med Virol; 2015 Feb; 87(2):315-22. PubMed ID: 25138591
[TBL] [Abstract][Full Text] [Related]
20. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
